Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07646717 Irinotecan Hydrochloride Lioposome Intrahepatic Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07646717 clinical trial report covering Irinotecan Hydrochloride Lioposome, Phase 2, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07647289 Enfortumab Vedotin-ejfv Locally Advanced Bladder Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647289 clinical trial report covering Enfortumab Vedotin-ejfv, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647263 Trastuzumab Rezetecan HER2 Positive Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647263 clinical trial report covering Trastuzumab Rezetecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647016 Trastuzumab Hormone receptor positive HER2 negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647016 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07646613 Dihydroergotamine Mesylate Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07646613 clinical trial report covering Dihydroergotamine Mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126751 Carboplatin Renal Pelvis and Ureter Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126751 clinical trial report covering Carboplatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647133 SAL-0140 Chronic Kidney Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647133 clinical trial report covering SAL-0140, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07648251 Furosemide Pre-Eclampsia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07648251 clinical trial report covering Furosemide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647653 Olaparib HRD-positive Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647653 clinical trial report covering Olaparib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07651618 Fludarabine Phosphate Malignant melanoma, metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07651618 clinical trial report covering Fludarabine Phosphate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07711314 Rezvilutamide Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07711314 clinical trial report covering Rezvilutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07664839 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07664839 clinical trial report covering Venetoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.